Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Fenner

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Nature Materials|March 23, 2012
One-click science marketingMartin Fenner
Nature|March 7, 2008
Duplication: stop favouring applicant with longest listMartin Fenner
Plos Biology|October 30, 2013
What can article-level metrics do for you?Martin Fenner
BMC Cancer|May 23, 2012
Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST)Christoph Seidel, Martin Fenner, Florian Länger, et al.
Onkologie|March 2, 2011
Retrospective analyses of patient characteristics having predictive impact on survival under everolimusChristoph Seidel, Martin Fenner, Christoph Reuter, et al.
European Journal of Cancer (Oxford, England : 1990)|March 23, 2012
Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinomaChristoph Seidel, Jonas Busch, Steffen Weikert, et al.
World Journal of Urology|March 16, 2010
Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancerChristoph W M Reuter, Michael A Morgan, Philipp Ivanyi, et al.
Patterns (New York, N.Y.)|January 29, 2021
Connected Research: The Potential of the PID GraphHelena Cousijn, Ricarda Braukmann, Martin Fenner, et al.
Onkologie|June 1, 2011
Efficacy of sunitinib re-exposure after failure of an mTOR inhibitor in patients with metastatic RCCViktor Grünwald, Steffen Weikert, Christoph Seidel, et al.
Journal of Cancer Research and Clinical Oncology|September 21, 2018
Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study GroupMartin Fenner, Christoph Oing, Annette Dieing, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Nature Materials|March 23, 2012
One-click science marketingMartin Fenner
Nature|March 7, 2008
Duplication: stop favouring applicant with longest listMartin Fenner
Plos Biology|October 30, 2013
What can article-level metrics do for you?Martin Fenner
BMC Cancer|May 23, 2012
Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST)Christoph Seidel, Martin Fenner, Florian Länger, et al.
Onkologie|March 2, 2011
Retrospective analyses of patient characteristics having predictive impact on survival under everolimusChristoph Seidel, Martin Fenner, Christoph Reuter, et al.
European Journal of Cancer (Oxford, England : 1990)|March 23, 2012
Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinomaChristoph Seidel, Jonas Busch, Steffen Weikert, et al.
World Journal of Urology|March 16, 2010
Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancerChristoph W M Reuter, Michael A Morgan, Philipp Ivanyi, et al.
Patterns (New York, N.Y.)|January 29, 2021
Connected Research: The Potential of the PID GraphHelena Cousijn, Ricarda Braukmann, Martin Fenner, et al.
Onkologie|June 1, 2011
Efficacy of sunitinib re-exposure after failure of an mTOR inhibitor in patients with metastatic RCCViktor Grünwald, Steffen Weikert, Christoph Seidel, et al.
Journal of Cancer Research and Clinical Oncology|September 21, 2018
Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study GroupMartin Fenner, Christoph Oing, Annette Dieing, et al.
Pageof 2